## **Supplementary Information**

## **Log-transformed concentrations**

A simple log-transformed concentration,  $D = log_{10}(d)$ , leaves the control out of the analysis (because  $d = 0$  for the control). Therefore, the objective was then to find an appropriate transformation that includes the control data in the fit and that keeps the points evenly spaced apart. Therefore, given a vector of *m* concentration points  $(d_i, i = 1$  to m, with  $d_1 = 0$  being the control) we defined a transformed concentration,  $D = \log(nd + 1)$ , where  $n = (\delta - 1)/d_2$  with  $d_2$ being the lowest non-zero dose in the experiment;  $\delta = d_m/d_{m-1}$ , where  $d_m$  and  $d_{m-1}$  are the last and penultimate dose points, respectively (EPA, 2012). This transformation ensured that concentration points were evenly spaced apart. Specifically, the difference between the 1<sup>st</sup> and  $2<sup>nd</sup>$  transformed concentration ( $D_2 - D_1 = \log(\delta)$ ) was roughly equal to the difference between the  $m<sup>th</sup>$  and  $m<sup>-1</sup>$ <sup>th</sup> transformed concentration  $(D_m - D_{m-1} = \log(nd_m + 1) - \log(nd_{m-1} + 1) \sim \log(d_m/d_{m-1}) =$ log(δ)). We used the transformed concentration, *D*, to visualize the plots of all the model fits to the data.

## **Supplementary Figures**



**Figure S1.** Workflow showing the statistical criteria applied for evaluating the data and the quality of model fits.



Figure S2. Concentration-response (C-R) curve-fit results showing the response probability versus scaled (log-transformed) dose of cymoxanil (TX001425) for morphology/mortality endpoints: (A) C-R curve with bad fit; (B) C-R curves with good or ok fits and  $BMD_{10}$  values > 1000 (in-active); (C) C-R curves with OK fits and good  $BMD_{10}$  values ( $0 < BMD_{10} \le 1000$ ). (D) C-R curves with good fits and good  $BMD_{10}$  values.



**Figure S3.** Proportion of abnormal fish versus log-transformed concentration plot and BMD<sub>10</sub> value of flusilazole (TX000669) for the MOV<sub>21</sub> (A) and AUC<sub>21</sub> (B) endpoints.



## Endpoint

Figure S4. Hierarchical clustering result based on the BMD<sub>10</sub> values of all zebrafish chemicalendpoint pairs. Heat map color bar represents  $-\log_{10}(BMD_{10})$  values.



Figure S5. Comparison between the BMD<sub>10</sub> values obtained with and without abnormally behaving malformed fishes for the  $MOV_{21}(A)$  and  $AUC_{21}(B)$  endpoints.



**Figure S6.** Venn diagram showing the number of chemicals that were most active through the behavioral endpoints when BMD10 values were calculated with and without abnormally behaving malformed fishes. Diagram created using Venny v. 2.1 [\(http://bioinfogp.cnb.csic.es/tools/venny/\)](http://bioinfogp.cnb.csic.es/tools/venny/)



**Figure S7.** Number of chemicals in each quartile range of BMD<sub>10</sub> values and their LEL range for the two most sensitive endpoints: (A)  $MOV_{21}$  (963 chemicals) and (B)  $AUC_{21}$  (934 chemicals). The inactive chemicals based on LEL are indicated as 'No LEL' and based on  $BMD_{10}$  values are indicated as  $BMD_{10} = 10^4$ .



**Figure S8.** Concentration-response plots for the chemical Quinoline (TX002359) based on  $MOV_{21}$  (A) and  $AUC_{21}$  (B) endpoints. The chemical ranking changed from 7 to 89 when the MOV21 and AUC21 BMD10 values were added to the *in vitro* ToxCast AC50 values in the ToxPi chemical ranking analysis.